Abacavir lamivudine zidovudine: Difference between revisions
Gerald Chi (talk | contribs) Created page with "__NOTOC__" |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Abacavir lamivudine zidovudine}} | |||
'''''For patient information, click <u>[[Abacavir lamivudine zidovudine (patient information)|here]]</u>'''''. | |||
{{CMG}}; {{AE}} {{SS}} | |||
==Overview== | |||
==Category== | |||
Antiretroviral | |||
==US Brand Names== | |||
TRIZIVIR<sup>®</sup> | |||
==FDA Package Insert== | |||
''' [[Abacavir lamivudine zidovudine description|Description]]''' | |||
'''| [[Abacavir lamivudine zidovudine clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Abacavir lamivudine zidovudine microbiology|Microbiology]]''' | |||
'''| [[Abacavir lamivudine zidovudine indications and usage|Indications and Usage]]''' | |||
'''| [[Abacavir lamivudine zidovudine contraindications|Contraindications]]''' | |||
'''| [[Abacavir lamivudine zidovudine warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[Abacavir lamivudine zidovudine adverse reactions|Adverse Reactions]]''' | |||
'''| [[Abacavir lamivudine zidovudine drug interactions|Drug Interactions]]''' | |||
'''| [[Abacavir lamivudine zidovudine overdosage|Overdosage]]''' | |||
'''| [[Abacavir lamivudine zidovudine clinical studies|Clinical Studies]]''' | |||
'''| [[Abacavir lamivudine zidovudine dosage and administration|Dosage and Administration]]''' | |||
'''| [[Abacavir lamivudine zidovudine how supplied|How Supplied]]''' | |||
'''| [[Abacavir lamivudine zidovudine labels and packages|Labels and Packages]]''' | |||
==Mechanism of Action== | |||
'''Abacavir''': Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted by cellular enzymes to the active metabolite, carbovir triphosphate (CBV-TP), an analogue of deoxyguanosine-5′-triphosphate (dGTP). CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. The lack of a 3′-OH group in the incorporated nucleotide analogue prevents the formation of the 5′ to 3′ phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. CBV-TP is a weak inhibitor of cellular DNA polymerases α, β, and γ. | |||
'''Lamivudine''': Lamivudine is a synthetic nucleoside analogue. Intracellularly, lamivudine is phosphorylated to its active 5′-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is inhibition of RT via DNA chain termination after incorporation of the nucleotide analogue. 3TC-TP is a weak inhibitor of cellular DNA polymerases α, β, and γ. | |||
'''Zidovudine''': Zidovudine is a synthetic nucleoside analogue. Intracellularly, zidovudine is phosphorylated to its active 5′-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). The principal mode of action of ZDV-TP is inhibition of RT via DNA chain termination after incorporation of the nucleotide analogue. ZDV-TP is a weak inhibitor of the cellular DNA polymerases α and γ and has been reported to be incorporated into the DNA of cells in culture. | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Antiretroviral]] | |||
[[Category:Wikinfect]] | |||
Revision as of 15:56, 9 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Overview
Category
Antiretroviral
US Brand Names
TRIZIVIR®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Abacavir: Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted by cellular enzymes to the active metabolite, carbovir triphosphate (CBV-TP), an analogue of deoxyguanosine-5′-triphosphate (dGTP). CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. The lack of a 3′-OH group in the incorporated nucleotide analogue prevents the formation of the 5′ to 3′ phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. CBV-TP is a weak inhibitor of cellular DNA polymerases α, β, and γ.
Lamivudine: Lamivudine is a synthetic nucleoside analogue. Intracellularly, lamivudine is phosphorylated to its active 5′-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is inhibition of RT via DNA chain termination after incorporation of the nucleotide analogue. 3TC-TP is a weak inhibitor of cellular DNA polymerases α, β, and γ.
Zidovudine: Zidovudine is a synthetic nucleoside analogue. Intracellularly, zidovudine is phosphorylated to its active 5′-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). The principal mode of action of ZDV-TP is inhibition of RT via DNA chain termination after incorporation of the nucleotide analogue. ZDV-TP is a weak inhibitor of the cellular DNA polymerases α and γ and has been reported to be incorporated into the DNA of cells in culture.